Asia Startup Funding Rounds
Startups raising capital across Asia. Compare the businesses, funding stages and investors active in the region.
- Rounds
- 411 Jan 1 – Oct 9, 2026
- Disclosed funding
- $13.2B 247 disclosed amounts
- Median round
- $8M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| S Combines travel booking with co-branded credit cards and mobile payments | $63M | Series CSeries C+ | Fintech | India | Investors | |
| S SignalPlusCompany profile Provides institutional digital assets options and derivatives trading infrastructure Provides institutional digital assets options and derivatives trading infrastructure | $40M | StrategicUndisclosed | Fintech | China | Investors | |
| FB Forlong BiotechnologyCompany profile Clinical-stage biotech developing cytokine therapies including IL-15 and IL-18 programs for cancer Clinical-stage biotech developing cytokine therapies including IL-15 and IL-18 programs for cancer | $17.5M | Pre-Series BUndisclosed | Biotech | China | Investors | |
| A AEONCompany profile AEON develops blockchain payment and settlement infrastructure that lets AI agents transact with services and merchants. AEON develops blockchain payment and settlement infrastructure that lets AI agents transact with services and merchants. | $8M | Pre-SeedPre-seed | Fintech | Hong Kong | Investors | |
| FT Full-Life TechnologiesCompany profile Clinical-stage radiotherapeutics company developing targeted cancer therapies with integrated isotope manufacturing Clinical-stage radiotherapeutics company developing targeted cancer therapies with integrated isotope manufacturing | $150M | Series D+DebtUndisclosed | Biotech | China | Investors | |
| DT Degron TherapeuticsCompany profile Develops molecular glue degrader medicines targeting previously undruggable proteins Develops molecular glue degrader medicines targeting previously undruggable proteins | $40M | Series A+Series A | Biotech | China | Investors | |
| YT Yitai TechnologyCompany profile Yitai Technology develops spatial data infrastructure for training robotics and embodied-AI models. Yitai Technology develops spatial data infrastructure for training robotics and embodied-AI models. | Undisclosed | Gaoxintou investment dated 11 May 2026Undisclosed | AI | China | Investors | |
| C Provides data for robotics foundation models | $27M | Seed | AI | South Korea | Investors | |
| AS Antier SolutionsCompany profile Antier Solutions engineers blockchain and digital-asset infrastructure for enterprises, financial institutions and public-sector organizations. Antier Solutions engineers blockchain and digital-asset infrastructure for enterprises, financial institutions and public-sector organizations. | $3M | Undisclosed | Fintech | India | Investors | |
| R ROBOTERACompany profile Builds humanoid robots with fully in-house hardware for logistics and industrial deployment at scale Builds humanoid robots with fully in-house hardware for logistics and industrial deployment at scale | $200M | Growth | Robotics | China | Investors AlibabaBAIC +25CDH Venture and Growth CapitalChina Unicom-affiliated fundsCICC CapitalDongfeng Asset InvestmentGaocheng CapitalGeely CapitalGolden Resources GroupHaierHillhouse InvestmentHorizon InvestmentHSGICBC CapitalIDG CapitalJingming CapitalKENGICLenovoLongqi InvestmentLuxin Venture Capital GroupSF GroupSingtel Innov8SparkEdge CapitalTsinghua Holding Tiancheng Asset ManagementUnite Pioneers CapitalWoori Financial HoldingsWoori Venture Partners |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1HSG
Manus, Anew Labs, Math Magic
9rounds1led - 2IDG Capital
Manus, Anew Labs, Apex Intelligence
9rounds3led - 3Japan Finance Corporation
MUKA, indent, Intentia, Inc.
8rounds0led - 4Peak XV Partners
Nua, Mokobara, Ringg AI
8rounds2led - 5Qiming Venture Partners
Vivacta Biotechnology, Pulnovo Medical, Vivatides Therapeutics
8rounds—led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.